Cancer Therapy

Cancer Immunotherapy

Cancer Immunotherapy

What is cancer immunotherapy?

“Cancer immunotherapy” is a type of therapy that utilizes the power of the body’s own immune system to attack or eliminate cancer.

According to Japan’s cancer statistics (Cancer Registry and Statistics, National Cancer Center), the number of new cancer patients (cancer incidence) has been increasing since 1985; in 2020, it is estimated to exceed 1,000,000, approximately triple the number in 1985.
On the contrary, the survival rate is increasing with the remarkable progress of medicine.
However, a certain number of patients do not respond to the currently available standard therapies such as surgery, chemotherapy (anticancer drugs), and radiotherapy.
Under such circumstances, “cancer immunotherapy,” which uses our natural “immune system” to eliminate bacteria and viruses that invade our body, is attracting attention worldwide as a new option.

In recent years, “cancer immunotherapy” has made great progress in cancer treatment as a therapy for intractable/advanced cancer that is difficult to treat using the existing standard therapies. To date, efforts for “personalized cancer treatment” have begun to provide optimal “cancer immunotherapy” for each patient by analyzing their profile, such as immune response, cancer cells, and cancer tissue environment, under dramatic advances in genetic analysis technologies.
At NEO Clinic Tokyo, we offer next-generation tailored cancer immunotherapy following the basic policy of “precision medicine.”

Combined Immunotherapy for Cancer

At NEO Clinic Tokyo, we offer “combined immunotherapy for cancer” suitable for each patient following the policy of “precision medicine,” primarily using neoantigen peptide vaccine therapy and oncoantigen peptide vaccine therapy, combined with cancer immunotherapy, cytokine therapy, immune checkpoint inhibitor therapy, and molecular targeted therapy.

The following three major types of immunotherapies for cancer are appropriately combined to maximize the therapeutic effect:

A type that enhances the immune system’s ability to attack cancerNeoantigen peptide vaccine therapy
Oncoantigen peptide vaccine therapy
Cancer Immunotherapy
Cytokine therapy
A type that restores the immune system’s ability to attack cancer compromised by cancerImmune checkpoint inhibitor therapy
A type that stops immunosuppression caused by cancer– Low-dose anticancer drugs
– Antibody therapy
Molecular targeted therapy
Cancer Immunotherapy (Neo T cell therapy[αβT-cell therapy])
Cytokine therapy

Clinical Research/Clinical Studies/Clinical Reports by Doctors at Our Clinic

Flow of Combined Immunotherapy for Cancer

The following illustrates the general flow of combined immunotherapy for cancer, focusing on neoantigen peptide vaccine therapy and oncoantigen peptide vaccine therapy:

Collect cancer tissues, specimens, or blood

In case of the neoantigen peptide vaccine therapy

Cancer tissues, specimens, or blood will be collected by surgery or biopsy.

In case of the oncoantigen peptide vaccine therapy

Blood samples will be collected

Cancer antigen will be identified.

In case of the neoantigen peptide vaccine therapy

Neoantigen is identified based on the results of genomic analysis.

In case of the oncoantigen peptide vaccine therapy

Oncoantigen is identified based on the results of blood test.

Synthesis of peptide

Addition of an immunostimulant

Subcutaneous injection of peptide vaccine

Options:

  • Low-dose anticancer drug therapy
  • Antibody therapy
  • Molecular targeted drug
  • Cancer Immunotherapy
  • Cytokine therapy
  • Immune checkpoint inhibition therapy

Can be added.

Example schedule of combined immunotherapy for cancer

Example 1: In case of primarily focusing on the neoantigen peptide vaccine therapy

Genomic analysis, etc.About 1 month Cancer tissues, specimens, or blood will be collected by surgery or biopsy
Genomic analysis/neoantigen identification
Options available during genomic analysisTo stop immunosuppression
– Low-dose anticancer drug/antibody therapy
– Molecular targeted drug/cytokine therapy
Peptide synthesisAbout 2–4 weeks Neoantigen peptide synthesis
VaccinationAbout 1.5–3 months An immunostimulant is added.

The neoantigen peptide vaccine is subcutaneously injected.

Option(s)– Cancer Immunotherapy
– Immune checkpoint inhibitor therapy

Example 2: if primarily focusing on the oncoantigen peptide vaccine therapy

Blood test, etc.About 1–2 weeks Blood samples will be collected.
Hematologic test/oncoantigen identification
Peptide synthesisAbout 2–4 weeks Oncoantigen peptide synthesis
VaccinationAbout 1.5–3 months An immunostimulant is added.

The oncoantigen peptide vaccine is subcutaneously injected.

Option(s)

– Immune checkpoint inhibitor therapy
– Low-dose anticancer drug/antibody therapy
– Cancer Immunotherapy
– Molecular targeted drug/cytokine therapy

Concomitant use with other treatments

“Cancer immunotherapy” and “molecular targeted therapy” can be expected to generate synergistic effects and become more effective by appropriately combining them with the three major standard therapies: surgical procedure (surgery), chemotherapy (anticancer drugs), and radiotherapy.

Patient’s medical information is considered to determine the most effective treatment method and the schedule of treatment.

Selection of treatments included in combined immunotherapy for cancer by disease stage and goal

At NEO Clinic Tokyo, we offer “combined immunotherapy for cancer,” based on “peptide vaccine therapy,” such as neoantigen peptide vaccine therapy or oncoantigen peptide vaccine therapy, according to the patient’s disease stage and treatment goal.
Individual treatment plans are formulated according to the disease stage and goal of each patient, for example, a current standard therapy received for advanced cancer, unresponsiveness to anticancer drugs, and willingness to prevent recurrence after surgery.
The following treatment menus are examples. The drugs and schedule used for the actual treatment vary depending on the patient.